Details of the Drug-Related molecule(s) Interaction Atlas
General Information of Drug (ID: DMDRT0E)
Drug Name | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Emanil; Herpesil; Herpidu; Idossuridina; Iododeoxyuridine; Kerecide; Ophthalmadine; Synmiol; ID2; LT00440811; SKF 14287; Dendrid (TN); HERPLEX (TN); Herpe-Gel; Herpes-Gel; Iododeoxyuridine-125I; Oftan-IDU; SK&F 14287; SK&F-14287; Idoxuridine (JP15/USP/INN); Idoxuridine [USAN:INN:BAN:JAN]; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 1-(2-deoxypentofuranosyl)-4-hydroxy-5-iodopyrimidin-2(1H)-one; 1-(2-deoxypentofuranosyl)-5-iodopyrimidine-2,4(1h,3h)-dione; 1-(4-Hydroxy-5-hydroxymethyltetrahydrofuran-2-yl)-5-iodo-1H-pyrimidine-2,4-dione; 1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 1.beta.-D-2'-Deoxyribofuranosyl-5-iodouracil; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 2'-Deoxy-5-(iodo-125I)uridine; 2'-deoxy-5-(125i)iodouridine; 5-(125-I)-Iodo-2-deoxyuridine; 5-I-2'-dUrd; 5-Iododesoxyuridine; 5IdU
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Therapeutic Class |
Antiviral Agents
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecule-Related Drug Atlas
Molecule-Related Drug Atlas
Molecule Type:
DTT DOT Drug Status:
Approved Drug(s) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Molecular Interaction Atlas | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
Drug Off-Target (DOT) |
|
||||||||||||||||||||||||||
References